Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: A meta-analytic approach

Statistics in Medicine

Volumn 26, Issue 8, 2007, Pages 1775-1787

  Fu, Rongwei ^a,b   Harris, Emily L ^a,c,f   Helfand, Mark ^a,d   Nelson, Heidi D ^a,b,e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c CENTER FOR HEALTH RESEARCH   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

^e Providence Health and Services   (United States)

^f NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

BRCA mutations; Breast cancer risk; Family history; Meta analysis; Penetrance; Prevalence

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

AGE DISTRIBUTION; ARTICLE; BAYES THEOREM; BREAST CANCER; CANCER RISK; CANCER STATISTICS; CANCER SUSCEPTIBILITY; FAMILY HISTORY; FEMALE; GENE MUTATION; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; JEW; PENETRANCE; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL;

EID: 33947405732     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2811     Document Type: Article

References (39)

1. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MRE, Easton DF, Venter DJ, The Australian Breast Cancer Family Study. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Cancer Epidemiology Biomarkers and Prevention 1999; 8(9):741-747.
2. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. British Journal of Cancer 2000; 83(10):1301-1308.
3. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. Journal of the National Cancer Institute 2002; 94(18): 1365-1372.
4. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New England Journal of Medicine 1997; 336(20):1401-1408.
5. King MC, Marks JH, Mandell JB for the New York Breast Cancer Study group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302(5645):643-646.
6. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. Journal of the National Cancer Institute 1999; 91(14):1241-1247.
7. Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiology Biomarkers and Prevention 2001; 10(5):467-473.
8. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Aranson A, Scherneck S, Peto J, Rabbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M. The Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. American Journal of Human Genetics 1998; 62(3):676-689.
9. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343:692-695.
10. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The breast cancer linkage consortium. American Journal of Human Genetics 1993; 52:678-701.
11. Wacholder S, Hartge P, Struewing JP, Pee D, McAdams M, Brody L, Tucker M. The kin-cohort study for estimating penetrance. American Journal of Epidemiology 1998; 148(7):623-630.
12. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics 2003; 72(5):1117-1130 (erratum appears in American Journal of Human Genetics 2003; 73(3):709).
13. DevCan: probability of developing or dying of cancer software. Statistical Research and Application Branch, National Cancer Institute, 2005. http://srab.cancer.gov/devcan/ as of 04/20/2005
14. Fay MP, Pfeiffer R, Cronin KA, Le C, Feuer EJ. Age-conditional probabilities of developing cancer. Statistics in Medicine 2003; 22:1837-1848.
15. Nelson HD, Huffman LH, Fu R, Harris EL, Walker M, Bougatsos C. Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility Systematic Evidence Synthesis. Agency for Healthcare Research and Quality: Rockville, MD, 2005. http://www.ahrq.gov/downloads/ pub/prevent/pdfser/brcagensyn.pdf as of 09/28/2006
16. Nelson HD, Huffman LH, Fu R, Harris EL. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. preventive services task force. Annuals of Internal Medicine 2005; 143:362-376.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7:177-188.
18. Egan KM, Newcomb PA, Longnecker MP, Trentham-Dietz A, Baron JA, Trichopoulos D, Stampfer MJ, Willett WC. Jewish religion and risk of breast cancer. Lancet 1996; 347:1645-1646.
19. Feldman GE. Do Ashkenazi Jews have a higher than expected cancer burden? Implications for cancer control prioritization efforts. Israel Medical Association Journal 2001; 3(5):341-346.
20. Neuhausen SL. Ethnic difference in cancer risk resulting from genetic variation. Cancer 1999; 86(Suppl. 11): 2575-2582.
21. Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST, Eng CM. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. American Journal of Human Genetics 1998; 63(1):45-51.
22. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics 1996; 14:185-187.
23. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 per cent in Ashkenazi Jewish individuals. Nature Genetics 1995; 11:185-187.
24. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1 per cent. Nature Genetics 1996; 14(2):188-190.
25. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. American Journal of Human Genetics 1999; 64(4):963-970.
26. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60 per cent of ovarian cancer and 30 per cent of early-onset breast cancer patients among Ashkenazi women. American Journal of Human Genetics 1997; 60(3):505-514.
27. FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend BH, Haber DA. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. New England Journal of Medicine 1996; 334(3):143-149.
28. Gershoni-Baruch R, Dagan E, Fried G, Bruchim Bar-Sade R, Sverdlov-Shiri R, Zelicksson G, Friedman E. Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer. European Journal of Cancer 2000; 36(8):983-986.
29. Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K. BRCA-associated breast cancer in young women. Journal of Clinical Oncology 1998; 16: 1642-1649.
30. Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. European Journal of Cancer 2000; 36(10):1200-1208.
31. Liede A, Karlan BY, Baldwin RL, Platt LD, Kuperstein G, Narod SA. Cancer incidence in a population of Jewish women at risk of ovarian cancer. Journal of Clinical Oncology 2002; 20(6):1570-1577.
32. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10 000 individuals. Journal of Clinical Oncology 2002; 20(6):1480-1490.
33. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. Lancet 2001; 358(9291): 1389-1399.
34. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. International Journal of Cancer 1997; 71(5):800-809.
35. Toniolo PG, Kato I. Jewish religion and risk of breast cancer. Lancet 1996; 348:760.
36. Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA, McManus R, Neuhausen SL, Ford D, Wooster R, Cannon-Albright LA, Stratton MR, Goldgar DE. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. American Journal of Human Genetics 1997; 61:120-128.
37. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Annnals of Internal Medicine 2005; 143:355-361.
38. Kerber RA, Slattery ML. Comparison of self-reported and database-linked family history of cancer data in a case-control study. American Journal of Epidemiology 1997; 146:244-248.
39. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. Journal of the National Cancer Institute 2002; 94(16):1221-1226.